Last updated: October 24, 2026
SURVANTA, or beractant, is a bovine lung extract used to prevent and treat respiratory distress syndrome in premature neonates. Its commercial profile is mature and declining: demand remains clinically relevant, but revenue is constrained by competition from Curosurf and Infasurf, changes in neonatal respiratory practice, and the absence of meaningful remaining exclusivity. AbbVie does not report SURVANTA revenue separately, so its financial trajectory must be assessed through product positioning, market access, and broader company disclosures rather than a standalone sales series.
What is SURVANTA and how is it used?
SURVANTA is an intratracheal suspension containing beractant, a biologic surfactant derived from bovine lung tissue. It is administered to premature infants with respiratory distress syndrome caused by pulmonary surfactant deficiency.
The product is supplied in single-use vials at a concentration of 25 mg/mL. The labeled dose is 100 mg phospholipid per kilogram of birth weight, equivalent to 4 mL/kg. Up to four doses may be administered during the first 48 hours of life when clinically indicated. The product requires refrigeration and preparation before intratracheal administration. [1]
| Attribute |
SURVANTA profile |
| Active ingredient |
Beractant |
| Product type |
Animal-derived pulmonary surfactant |
| Route |
Intratracheal |
| Primary indication |
Prevention and treatment of neonatal respiratory distress syndrome |
| Original sponsor |
Abbott Laboratories |
| Current commercial association |
AbbVie legacy product portfolio |
| FDA approval |
1991 |
| NDA |
019810 |
| Main alternatives |
Curosurf, Infasurf |
| Patient population |
Premature neonates, especially very-low-birth-weight infants |
SURVANTA is used in both prophylactic and rescue settings, although neonatal practice has shifted toward selective administration based on respiratory status rather than routine prophylaxis for all high-risk infants.
When did SURVANTA receive FDA approval?
The FDA approved SURVANTA in 1991. Its approval established beractant as one of the first widely used exogenous pulmonary surfactants for neonatal respiratory distress syndrome. The approval predates the current biosimilar framework and the modern regulatory structure for many biologic products.
The product’s regulatory age has commercial consequences. The principal composition, dosing concept, and core clinical use have been established for decades. No remaining regulatory exclusivity period protects the original product.
SURVANTA’s FDA-approved labeling continues to identify beractant as an intratracheal treatment for respiratory distress syndrome in premature infants. The label also describes adverse events associated with administration, including transient oxygen desaturation, bradycardia, airway obstruction, and the need for ventilatory adjustment. [1]
What is the current FDA and Orange Book status of SURVANTA?
SURVANTA is associated with an FDA-approved new drug application rather than a recently approved biologic with active reference-product exclusivity. The product’s NDA is 019810. FDA labeling and product information remain the principal public sources for its regulatory status. [1]
The Orange Book framework is less central for SURVANTA than it is for conventional small-molecule products. SURVANTA is an animal-derived surfactant and is regulated as a complex biological product, which creates technical barriers that are not fully captured by ordinary small-molecule equivalence analysis.
No current six-month or four-year exclusivity period protects SURVANTA. Any commercial protection would therefore depend on manufacturing know-how, supply reliability, clinical familiarity, contracting, and product-specific regulatory barriers rather than statutory exclusivity.
What patents protect SURVANTA?
The original patent estate for beractant and its core use is mature. The 1991 approval date means that patents covering the original composition, extraction methods, and early clinical applications would generally have expired by now, assuming ordinary patent terms and no unusual term extensions.
Publicly available product materials do not identify a current, high-value patent barrier that would prevent competition with the core SURVANTA product. The product’s commercial defensibility is more likely to arise from:
- Complex extraction and purification of bovine lung material.
- Control of phospholipid composition and surfactant protein content.
- Sterility and viral or adventitious-agent controls.
- Consistency across animal-derived raw-material lots.
- Stability during refrigerated storage.
- Manufacturing scale and validated fill-finish operations.
- Hospital familiarity and neonatal intensive-care-unit protocols.
These barriers can delay or complicate entry even when composition patents have expired. They do not create the same legal exclusivity as an unexpired patent.
Does SURVANTA have formulation patents?
The commercial formulation is a suspension of beractant in saline with associated phospholipids and surfactant proteins. Any legacy formulation patents are unlikely to provide long-term exclusivity today. A later patent could theoretically cover a manufacturing improvement, container, stability profile, or administration technique, but no publicly established later patent position appears to define the market.
For valuation purposes, SURVANTA should be treated as a technology with manufacturing barriers rather than as a product supported by a durable formulation-patent moat.
Are there Paragraph IV challenges or generic competitors to SURVANTA?
There is no broadly recognized active Paragraph IV litigation campaign against SURVANTA comparable to those involving major small-molecule blockbusters.
A conventional generic competitor would face technical questions involving:
- Biological source material.
- Surfactant composition.
- Protein and lipid characterization.
- Functional activity in neonatal lungs.
- Manufacturing consistency.
- Clinical and immunologic comparability.
- The FDA pathway used for a complex animal-derived product.
The absence of a prominent Paragraph IV challenge does not establish permanent protection. It indicates that development economics and technical complexity may be more important than patent litigation.
A competing product could enter through an abbreviated pathway if the FDA determines that the relevant legal and scientific standards are met. Alternatively, a sponsor may pursue a full application or another biologic pathway depending on product classification and development strategy. FDA’s Purple Book and Orange Book systems do not eliminate the need for product-specific regulatory analysis in this category. [2,3]
How does SURVANTA compare with Curosurf and Infasurf?
Curosurf, Infasurf, and SURVANTA compete in the same neonatal pulmonary surfactant market but differ in source material, surfactant protein content, dosing, and commercial positioning.
| Product |
Active ingredient |
Source |
Typical commercial strength |
Competitive position |
| SURVANTA |
Beractant |
Bovine lung extract |
25 mg/mL |
Established legacy product |
| Curosurf |
Poractant alfa |
Porcine lung extract |
80 mg/mL |
Strong competitor with higher-concentration dosing |
| Infasurf |
Calfactant |
Calf lung lavage |
35 mg/mL |
Established U.S. alternative |
Curosurf has benefited from concentrated dosing, broad international presence, and strong commercial execution by Chiesi. Infasurf remains a relevant alternative in the United States, particularly where neonatal protocols and institutional contracts support its use. [4,5]
SURVANTA’s principal disadvantages are its lower concentration relative to Curosurf, larger administration volume in some dosing scenarios, and its mature brand position. Its advantages include long clinical experience, established hospital familiarity, and inclusion in neonatal treatment protocols.
Direct head-to-head clinical comparisons have not produced a universal conclusion that one surfactant is superior for every premature infant. Outcomes depend on gestational age, dosing strategy, ventilation approach, timing of administration, and local clinical practice.
What market forces affect SURVANTA demand?
SURVANTA demand is tied to the number of premature births and the treatment rate for respiratory distress syndrome. The product is used in a concentrated hospital market, so neonatal intensive-care-unit purchasing decisions have an outsized effect on volume.
The principal market forces are:
- Prematurity incidence. More very-preterm and extremely-preterm births expand the addressable population.
- Selective surfactant use. Early continuous positive airway pressure and less-invasive ventilation can reduce routine prophylactic use.
- Administration technique. LISA and MIST approaches may support surfactant treatment while reducing invasive mechanical ventilation.
- Hospital contracting. Neonatal pharmacy committees and group purchasing organizations influence product selection.
- Competitor supply. Shortages or allocations involving Curosurf or Infasurf can temporarily shift demand to SURVANTA.
- Clinical guidelines. Recommendations increasingly emphasize early treatment of infants with respiratory distress rather than automatic treatment based only on birth weight.
- Manufacturing reliability. Animal-derived products require dependable raw-material sourcing, validated processing, and strict quality controls.
Demand is therefore relatively defensive but not immune to erosion. The product treats an acute neonatal condition, which limits discretionary prescribing, yet treatment protocols can reduce doses per patient.
What is the financial trajectory of SURVANTA?
AbbVie does not disclose standalone SURVANTA revenue, unit volume, gross margin, or profitability in its public financial reporting. The product is grouped within broader pharmaceutical portfolio disclosures, preventing a reliable product-level revenue reconstruction from annual reports. [6]
SURVANTA’s financial trajectory can be characterized as follows:
| Period |
Financial interpretation |
| 1990s |
Growth and adoption following approval of a first-generation neonatal surfactant |
| 2000s |
Mature product with competition from additional animal-derived surfactants |
| 2010s |
Portfolio maturity and increased competitive pressure from Curosurf |
| 2020s |
Stable clinical niche with limited public evidence of material growth |
The product is unlikely to be a major contributor to AbbVie’s consolidated revenue. AbbVie’s financial results are dominated by immunology, oncology, neuroscience, aesthetics, and other large pharmaceutical franchises. [6]
SURVANTA can still generate recurring revenue because neonatal intensive-care units maintain inventory and the product addresses a high-acuity condition. Its economics are less attractive than those of protected specialty medicines because:
- The product is old.
- The market is limited to neonatal critical care.
- Competing surfactants are established.
- Hospital buyers can negotiate on price and supply.
- No publicly visible exclusivity event is expected to create a sharp revenue step-up.
- Clinical practice can reduce prophylactic treatment volume.
What licensing deals affect SURVANTA?
SURVANTA originated in Abbott’s pharmaceutical and pediatric nutrition ecosystem and was carried into the AbbVie organization after Abbott separated its research-based pharmaceutical business in 2013. Public company disclosures do not identify a recent licensing transaction that materially changes SURVANTA’s ownership, commercial economics, or market access.
The product’s current value is therefore primarily operational rather than transaction-driven. A potential licensing or divestiture valuation would depend on regional rights, manufacturing capacity, supply commitments, and the buyer’s ability to place the product in neonatal hospital accounts.
No major public settlement agreement is associated with SURVANTA’s current commercial position.
What patent litigation affects SURVANTA?
No major active patent litigation is publicly associated with SURVANTA’s core product position. The legal risk profile is materially different from that of a recently launched small molecule with multiple Orange Book patents.
Potential disputes would more likely concern:
- Manufacturing processes.
- Product quality or contamination.
- Supply contracts.
- Trademark and branding.
- Regulatory classification.
- Substitution or reimbursement practices.
- Proprietary analytical methods.
There is no apparent current litigation event that would create a near-term launch block or materially alter SURVANTA’s market share.
What generic or biosimilar launch risks exist?
The relevant threat is a technically comparable surfactant, not necessarily a conventional generic tablet. A competing manufacturer would need to demonstrate adequate quality, identity, purity, potency, and clinical performance.
Biosimilar risk is limited in the near term by the complexity of animal-derived surfactant products and the small addressable market. The regulatory pathway is less predictable than for monoclonal antibodies with well-established biosimilar precedent. Even so, the absence of active patents means a capable manufacturer could pursue entry if the commercial opportunity justifies development costs.
The most credible entry scenario is a regional or specialized competitor that secures supply, develops a comparable formulation, and targets hospitals through contracting rather than a broad retail launch.
What manufacturing and geographic barriers protect SURVANTA?
SURVANTA’s manufacturing barriers are more important than geographic patent coverage. The product depends on animal-derived raw materials, specialized extraction, formulation, sterility control, and refrigerated distribution.
The main barriers include:
- Access to qualified bovine lung material.
- Consistent source-animal controls.
- Removal or control of contaminants.
- Preservation of biologically active surfactant proteins.
- Batch-to-batch potency testing.
- Validated aseptic processing.
- Cold-chain distribution.
- Regulatory inspections and process documentation.
Geographically, SURVANTA competes in hospital markets where regulatory approval, local reimbursement, tender systems, and neonatal guideline adoption determine access. The United States remains commercially important, but international sales depend on local registration and distributor or licensee arrangements.
How strong is the SURVANTA patent estate?
SURVANTA has a weak current patent estate and a moderate manufacturing position.
| Dimension |
Assessment |
| Core composition patents |
Mature or expired |
| Method-of-use patents |
Limited current value |
| Formulation patents |
No publicly apparent dominant barrier |
| Regulatory exclusivity |
Expired |
| Manufacturing know-how |
Meaningful |
| Hospital familiarity |
Meaningful |
| Biosimilar or complex-product entry risk |
Moderate over the long term |
| Near-term litigation risk |
Low based on public information |
| Revenue-growth potential |
Low |
| Revenue durability |
Moderate within a specialized hospital niche |
The product can retain commercial value without patent protection because neonatal surfactant supply is technically demanding and hospitals value predictable availability. That protection is operational, not legally exclusive.
What are the likely generic launch scenarios for SURVANTA?
The most likely scenarios are:
Base case: gradual erosion
SURVANTA remains available but loses share gradually to Curosurf, Infasurf, and less-invasive treatment protocols. Revenue declines slowly, with occasional volume increases caused by competitor shortages.
Downside case: accelerated substitution
A competitor improves contracting terms, a hospital system standardizes on another surfactant, or manufacturing disruption affects SURVANTA availability. Volume and revenue decline faster than the underlying birth or prematurity trend.
Upside case: supply-driven stabilization
Competitor shortages, procurement changes, or renewed use in selected neonatal protocols stabilize SURVANTA volume. This would support cash generation but would not establish a durable growth trajectory.
A large, sudden generic launch is less likely than incremental share movement because the market is specialized and the product is technically complex.
Key Takeaways
- SURVANTA is an established beractant product approved by the FDA in 1991.
- Its core patent and regulatory exclusivity position is mature.
- No major active Paragraph IV campaign or patent litigation is publicly associated with the product.
- AbbVie does not disclose standalone SURVANTA revenue.
- Revenue is likely stable to declining rather than expanding.
- Curosurf is the principal commercial competitor, with Infasurf also active in the market.
- Manufacturing complexity, quality controls, and hospital familiarity provide practical barriers to entry.
- Future erosion is more likely to come from clinical practice changes and contracting than from a single patent expiry event.
- SURVANTA remains commercially relevant in neonatal intensive care but is unlikely to be a material growth driver for AbbVie.
FAQs
Is SURVANTA still available in the United States?
SURVANTA remains an FDA-approved beractant product associated with NDA 019810. Availability depends on current manufacturer supply and hospital distribution.
Is SURVANTA a biosimilar?
SURVANTA is the original beractant product, not a biosimilar. A future competing product would need to satisfy the FDA’s applicable requirements for a complex biological or drug product.
Who competes directly with SURVANTA?
Curosurf, marketed by Chiesi, and Infasurf are the principal direct competitors in neonatal pulmonary surfactant therapy.
Does SURVANTA have an Orange Book patent expiry date?
The original SURVANTA exclusivity period has expired. The product’s commercial materials do not indicate a current Orange Book patent barrier that would provide meaningful market protection.
Why has SURVANTA not attracted more generic competition?
Development requires specialized animal-derived raw materials, complex characterization, clinical comparability, and reliable hospital distribution. The relatively narrow neonatal market may not justify those costs for every potential entrant.
References
-
U.S. Food and Drug Administration. (n.d.). SURVANTA (beractant) intratracheal suspension prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Chiesi Farmaceutici S.p.A. (n.d.). Curosurf prescribing information. https://www.curosurf.com/
-
U.S. Food and Drug Administration. (n.d.). INFASURF (calfactant) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investors.abbvie.com/financial-information/annual-reports-and-proxy-statements